Core Viewpoint - Beijing Baipusais Biotechnology Co., Ltd. plans to use 182.73 million yuan of remaining raised funds to permanently supplement its working capital and extend the implementation period of certain fundraising investment projects, which will be submitted for shareholder approval [1][2][3]. Fund Utilization - The board approved the use of 182.73 million yuan of remaining raised funds, which accounts for 15.79% of the total raised funds, to permanently supplement working capital [2]. - The funds include cash management income and net interest income, with the actual amount subject to the balance on the transfer date [2]. - The company assures that this fund usage will not conflict with the implementation plans of the fundraising investment projects and will not harm shareholder interests [2]. Project Implementation Extension - The board also approved the extension of the implementation period for certain fundraising investment projects, a decision made based on current market conditions and future development [3]. - This extension aims to better align with the company's long-term strategic planning without changing the direction of the raised funds [3]. - The adjustment has been confirmed by the sponsor institution as not harming the interests of the company and all shareholders [3]. Other Important Matters - The board approved the reappointment of Rongcheng Accounting Firm as the auditing institution for the 2025 financial report and internal control [4]. - A temporary shareholder meeting is scheduled for December 18, 2025, to review the related proposals [4]. - All board members participated in the voting, with all proposals passed unanimously, and the meeting procedures complied with relevant laws and regulations [4].
百普赛斯拟用1.83亿元剩余超募资金永久补流 同时延长部分募投项目期限